Medical Oncology, Department of Clinical and Experimental Medicine F. Magrassi & A. Lanzara, Second University of Naples, Naples, Italy.
Oncology. 2009;77 Suppl 1:38-42. doi: 10.1159/000258494. Epub 2010 Feb 2.
Although the incidence of gastric cancer has been declining in Western countries, it is still a major health problem and a leading cause of cancer mortality. Surgery is the mainstay of treatment for gastric adenocarcinoma. However, even among patients undergoing gastrectomy with curative intent, 5-year survival rates are disappointing due to locoregional relapse and distant metastases. This emphasizes the importance of multidisciplinary management of patients with gastric cancer. In contrast to the preoperative approach, several phase III trials have been carried out in the adjuvant setting, but postoperative chemotherapy has not proven to be superior to surgery alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed.
尽管在西方国家，胃癌的发病率一直在下降，但它仍然是一个主要的健康问题，也是癌症死亡的主要原因。手术是治疗胃腺癌的主要方法。然而，即使是在接受根治性胃切除术的患者中，由于局部复发和远处转移，5 年生存率仍令人失望。这强调了对胃癌患者进行多学科管理的重要性。与术前方法不同，已经在辅助治疗环境中开展了几项 III 期试验，但术后化疗并未被证明优于单独手术。因此，目前常规使用辅助治疗应被视为一种研究方法。需要改进临床试验设计，标准化手术技术，并纳入新的有效药物。
